Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Net Cash Flow (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Net Cash Flow for 7 consecutive years, with -$48.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 472.94% to -$48.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$25.7 million, a 423.65% decrease, with the full-year FY2025 number at -$25.7 million, down 423.65% from a year prior.
  • Net Cash Flow was -$48.3 million for Q4 2025 at Pliant Therapeutics, down from $6.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $68.8 million in Q1 2023 to a low of -$48.3 million in Q4 2025.
  • A 5-year average of -$197750.0 and a median of -$416500.0 in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 30249.21% in 2022, then skyrocketed 997.66% in 2025.
  • Pliant Therapeutics' Net Cash Flow stood at $6.4 million in 2021, then tumbled by 269.93% to -$10.9 million in 2022, then surged by 164.37% to $7.0 million in 2023, then plummeted by 219.75% to -$8.4 million in 2024, then crashed by 472.94% to -$48.3 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Net Cash Flow are -$48.3 million (Q4 2025), $6.9 million (Q3 2025), and -$5.1 million (Q2 2025).